Kareem Ali Maher, et al. “Cardiovascular Risk Assessment After Sofosbuvir and Daclatasvir Regimen for Chronic Hepatitis C Virus Infection”. Journal of the Pakistan Medical Association, vol. 73, no. 4, May 2023, pp. S136-S141, doi:10.47391/JPMA.EGY-S4-28.